Negative Regulation of Signal Transduction by G-CSF

G-CSF 对信号转导的负调控

基本信息

  • 批准号:
    6623659
  • 负责人:
  • 金额:
    $ 18.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-09-02 至 2007-06-30
  • 项目状态:
    已结题

项目摘要

Binding of granulocyte colony-stimulating factor (G-CSF) to its cognate receptor results in activation of multiple signal transduction pathways that are critical for the regulation of granulopoiesis. How G-CSF-activated signaling events are downmodulated is largely unknown. Mutations in the G-CSF receptor gene leading to its C-terminal truncation have been reported in patients with acute myeloid leukemia (AML), providing the first clinical evidence for the involvement of abnormal cytokine receptors in human leukemia. Expression of the truncated receptors in hematopoietic cells results in enhanced cell proliferation and survival but impaired myeloid differentiation in response to G-CSF. The truncated receptors also mediate dramatically augmented and/or prolonged activation of Stats and Akt, which play crucial roles in regulating cell proliferation and survival. Interestingly, substitution of the three C-terminal tyrosine residues with phenylalanine leads to prolonged but not enhanced activation of Stats and Akt whereas deficiency of tyrosine phosphatase SHP-1 is associated with enhanced but not prolonged Stat activation by G-CSF. We hypothesize that the magnitude and duration of Stat and Akt activation by G-CSF are downregulated by distinct negative regulatory mechanisms and that the C-terminal region of the G-CSF receptor may contain critical subdomains implicated in interactions with the negative regulatory mechanisms. Two specific aims are proposed to test this hypothesis: (1) to define the C-terminal subdomain required for the downregulation of the magnitude of Stat activation and examine the mechanism by which SHP-1 exerts its negative effect on Stat activation; and (2) to identify the C-terminal tyrosine residues involved in the negative regulation of the duration of Stat and Akt activation by G-CSF and investigate the roles of negative regulatory molecules such as SHP-2 and SHIP in G-CSF receptor signaling. The proposed research will improve our understanding of the regulatory network of G-CSF signaling and the molecular mechanisms by which C- terminal truncation of the G-CSF receptor contribute to leukemogenesis.
粒细胞集落刺激因子(G-CSF)与其同源受体结合可激活多条信号转导通路,这些信号转导通路对粒细胞生成的调控至关重要。G-CSF激活的信号事件是如何下调的在很大程度上是未知的。在急性髓系白血病(AML)患者中发现G-CSF受体基因突变导致其C端截短,这为人类白血病中异常细胞因子受体的参与提供了第一个临床证据。在造血细胞中表达截短的受体可以促进细胞的增殖和存活,但会影响G-CSF对髓系细胞的分化。被截断的受体还显著增强和/或延长了Stats和Akt的激活,这两个基因在调节细胞增殖和生存方面发挥着关键作用。有趣的是,用苯丙氨酸取代三个C端酪氨酸残基会导致Stats和Akt的激活延长但不会增强,而酪氨酸磷酸酶SHP-1的缺失与G-CSF增强但不会延长Stat的激活有关。我们假设G-CSF激活Stat和Akt的幅度和持续时间受到不同的负性调节机制的下调,G-CSF受体的C末端区域可能包含与负性调节机制相互作用的关键亚域。为了验证这一假说,提出了两个具体的目标:(1)确定下调Stat激活幅度所需的C末端亚域,并研究SHP-1对Stat激活的负面影响机制;(2)鉴定参与G-CSF对Stat和Akt激活持续时间的负调控的C末端酪氨酸残基,并研究SHP-2和Ship等负调控分子在G-CSF受体信号转导中的作用。这项拟议的研究将提高我们对G-CSF信号调控网络的理解,以及G-CSF受体C端截短促进白血病发生的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FAN DONG其他文献

FAN DONG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FAN DONG', 18)}}的其他基金

ELANE and CSF3R mutations in severe congenital neutropenia
严重先天性中性粒细胞减少症中的 ELANE 和 CSF3R 突变
  • 批准号:
    8367147
  • 财政年份:
    2012
  • 资助金额:
    $ 18.26万
  • 项目类别:
Gfi-1 in the regulation of p21Cip
Gfi-1 对 p21Cip 的调节
  • 批准号:
    7364781
  • 财政年份:
    2008
  • 资助金额:
    $ 18.26万
  • 项目类别:
Negative Regulation of Signal Transduction by G-CSF
G-CSF 对信号转导的负调控
  • 批准号:
    6469391
  • 财政年份:
    2002
  • 资助金额:
    $ 18.26万
  • 项目类别:
Negative Regulation of Signal Transduction by G-CSF
G-CSF 对信号转导的负调控
  • 批准号:
    6755890
  • 财政年份:
    2002
  • 资助金额:
    $ 18.26万
  • 项目类别:
Negative Regulation of Signal Transduction by G-CSF
G-CSF 对信号转导的负调控
  • 批准号:
    7078573
  • 财政年份:
    2002
  • 资助金额:
    $ 18.26万
  • 项目类别:
Negative Regulation of Signal Transduction by G-CSF
G-CSF 对信号转导的负调控
  • 批准号:
    6910017
  • 财政年份:
    2002
  • 资助金额:
    $ 18.26万
  • 项目类别:
Negative Regulation of Signal Transduction by G-CSF
G-CSF 对信号转导的负调控
  • 批准号:
    6686316
  • 财政年份:
    2002
  • 资助金额:
    $ 18.26万
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    $ 18.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了